Evidence map›Paper›PMID 41310951›Full record

ArticleArthritis & rheumatology (Hoboken, N.J.)2026

Dosing Biologic Drugs for Patients With Obesity: One Size Does Not Fit All.

Stephen J Balevic, Daniel Gonzalez, Bernd Meibohm

Abstract read
In one paragraph

Article in Arthritis & rheumatology (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Stephen J BalevicDuke Clinical Research Institute, Durham, North Carolina.ORCID https://orcid.org/0000-0002-4016-1680
Daniel GonzalezDuke Clinical Research Institute, Durham, North Carolina.
Bernd MeibohmDepartment of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis.

Funding

Application of Physiologically-Based Pharmacokinetic Modeling to Characterize Drug-Drug Interactions in InfantsR01HD102949 · NICHD · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Daniel Gonzalez · 2021 to 2026
$3.0M
PRISMR01HD113201 · NICHD · DUKE UNIVERSITY · PI Daniel Gonzalez, Jason E. Lang · 2023 to 2026
$2.7M
Physiologically-Based Pharmacokinetic Modeling to Guide Drug Dosing in Children with ObesityR01HD096435 · NICHD · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DUMOND, JULIE BRUMER · 2018 to 2022
$2.0M
Optimal Dosing for Biologic Agents in Obese Patients with Rheumatoid and Juvenile ArthritisK23AR075874 · NIAMS · DUKE UNIVERSITY · PI BALEVIC, STEPHEN JOSEPH · 2020 to 2024
$830k
NIAMS NIH HHS K23 AR075874NICHD NIH HHS HHSN275201000003CNICHD NIH HHS HHSN275201000003INICHD NIH HHS R01 HD096435NICHD NIH HHS R01 HD102949NICHD NIH HHS R01 HD113201NIH HHS 5K23AR075874
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID41310951
PMCPMC12890050

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.